Open access · OA
via OpenAlex
From Ageing Biology to Alzheimer’s Therapy: Integrating Geroscience, Lifestyle and Pharmacological Strategies
touchREVIEWS in Neurology · 2025
Abstract
I ntroduction:The biggest risk factor for Alzheimer's disease (AD) is ageing, contributing to impaired clearance of tau and amyloidbeta proteins, microglial senescence(definition), endoplasmic reticulum (ER) stress, lipid dysregulation and excitotoxicity.This article investigates how ageing speeds up the pathophysiology of AD and evaluates emerging geroscience-based interventions targeting biological ageing mechanisms to delay or prevent cognitive decline.Methods: A narrative review (January 2015 to September 2025) across PubMed, Embase, Cochrane and Google Scholar identified 79 eligible studies on ageing-related mechanisms in AD.Results: Key mechanisms included glymphatic dysfunction, apolipoprotein E (APOE) ε4 pathology, microglial senescence, ER stress, brain-derived neurotrophic factor depletion and excitotoxicity.Interventions ranged from lifestyle strategies (exercise, sleep and diet) to senolytics(definition), epigenetic modulators and stem cell therapies.Conclusion: Targeting ageing mechanisms offers a paradigm shift in AD prevention and treatment; however, multidisciplinary collaboration is essential to translate geroscience into clinical practice.The integration of lifestyle and pharmacological strategies may yield synergistic neuroprotective benefits.Future research should focus on integrated, multimodal interventions that combine lifestyle modification with pharmacological and biological therapies.Tailored approaches -based on genetic risk profiles (e.g.APOE status), comorbidities and individual ageing trajectories -may optimize clinical outcomes.To evaluate the long-term safety and effectiveness of innovative treatments such as senolytics, epigenetic modulators and stem cell-based therapies in older populations, extensive longitudinal clinical trials are required.Developments in biological age biomarkers, machine learning and systems biology have the potential to improve risk assessment and therapy customization.Between 60% and 80% of cases with dementia worldwide are caused by Alzheimer's disease (AD), making it the most prevalent type of dementia.1 As of 2025, approximately 60 million people worldwide are affected by dementia, and by 2050, projections suggest a rise to nearly 210 million.2 Age is the strongest risk factor, with AD affecting nearly half of those aged >85 years.3 In both the USA and Europe, the prevalence of AD increases with age, from 0.85% among individuals aged 65-69 years to 44.35% in those aged over 95 years.4 In addition to ageing, Figure 1 shows several other factors that contribute to AD risk, including female sex, genetic predisposition, low educational attainment, head injuries and lifestyle-related behaviours such as a sedentary lifestyle, smoking, alcohol use and obesity.These risk factors synergistically interact with ageing to promote the development of AD. 5 Despite years of research, the treatment of AD remains limited.This highlights the need for novel approaches that target the underlying pathophysiology.The biggest risk factor for AD is ageing, and targeting ageing processes may be more successful than amyloid-beta (Aβ)/phosphorylated tau (p-tau) strategies in altering the course of AD.This article critically evaluates the biological pathways through which ageing contributes to AD pathogenesis and examines innovative lifestyle and pharmacological interventions that target these processes. MethodsThis narrative review employed a structured, two-phase screening process.An initial screen of 250 titles and abstracts led to the exclusion of 150 records.A subsequent full-text review of the remaining 100 articles identified 30 duplicates, resulting in 79 studies for inclusion.A structured literature search was undertaken to identify these publications.Electronic databases
◌ CITATION ONLY
Full text is not openly licensed for redistribution here. Read it at the source:
Provenance
- Source
- OpenAlex
- DOI
- 10.17925/usn.2025.21.1.10
- Canonical
- link ↗
- Fetched
- 2026-10-28 MST
Cite this
APA
Abdel-Sater, K.A. (2025). From Ageing Biology to Alzheimer’s Therapy: Integrating Geroscience, Lifestyle and Pharmacological Strategies. <em>touchREVIEWS in Neurology</em>. https://doi.org/10.17925/usn.2025.21.1.10
Vancouver
Abdel-Sater KA. From Ageing Biology to Alzheimer’s Therapy: Integrating Geroscience, Lifestyle and Pharmacological Strategies. touchREVIEWS in Neurology. 2025. doi:10.17925/usn.2025.21.1.10.
BibTeX
@article{khaled2025FromAg,
title = {From Ageing Biology to Alzheimer’s Therapy: Integrating Geroscience, Lifestyle and Pharmacological Strategies},
author = {Khaled A. Abdel-Sater},
journal = {touchREVIEWS in Neurology},
year = {2025},
doi = {10.17925/usn.2025.21.1.10},
}
Research neighborhood
References, citing works, and semantically nearest findings. Click a node to open it.
Related findings
Biomedicines 2024
Open access · CC-BY
Exploring the Interconnection between Metabolic Dysfunction and Gut Microbiome Dysbiosis in Osteoarthritis: A Narrative Review
World journal of transplantation 2026
Open access · OA
Immunosenescence and cancer predisposition in pediatric transplant recipients: An emerging paradigm.
Lymphatics 2025
Open access · CC-BY
Biological Age, Aging Clocks, and the Interplay with Lymphoid Neoplasms: Mechanisms and Clinical Frontiers
Nutrients 2021
Open access · CC-BY
Therapeutic Potential of Mitophagy-Inducing Microflora Metabolite, Urolithin A for Alzheimer’s Disease
Frontiers in Aging 2021
Open access · CC-BY
Network Topology of Biological Aging and Geroscience-Guided Approaches to COVID-19
InTech eBooks 2018
Open access · CC-BY